Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis

Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-04, Vol.10 (4), p.e0124230-e0124230
Main Authors: Zhu, Lin, Yu, Hong, Liu, Shi-Yuan, Xiao, Xiang-Sheng, Dong, Wei-Hua, Chen, Yi-Nan, Xu, Wei, Zhu, Tong
Format: Article
Language:English
Subjects:
Analysis
Biomarkers, Tumor - metabolism
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - enzymology
Care and treatment
Confidence intervals
Female
Glycoproteins
Heterogeneity
Hospitals
Humans
Immunohistochemistry
Inhibitors
Lung cancer
Lung carcinoma
Lung diseases
Lung Neoplasms - enzymology
Male
Matrix metalloproteinase
Medical ethics
Medical imaging
Medical prognosis
Medical research
Meta-analysis
Metalloproteinase
Metastasis
Middle Aged
Mutation
Non-small cell lung cancer
Non-small cell lung carcinoma
Patients
Prognosis
Proteins
Small cell lung cancer
Small cell lung carcinoma
Subgroups
Survival
Systematic review
Test procedures
Tissue inhibitor of metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2 - metabolism
Tissues
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0124230